- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT06255782
Avoin tutkimus ECUR-506:n tutkimiseksi alle 9 kuukauden ikäisillä miesvauvoilla, joilla on vastasyntyneen OTC-puutos (OTC-HOPE)
Vaiheen I/II ensimmäinen ihmisessä, avoin, annoskorotustutkimus, jolla arvioitiin ECUR-506:n kerta-annon (IV) turvallisuutta ja tehokkuutta alle 9 kuukauden ikäisillä miehillä, joilla on geneettisesti vahvistettu vastasyntyneen alku Ornitiinitranskarbamylaasin (OTC) puutos
Ornithine Transcarbamylase (OTC) deficiency, the most common urea cycle disorder, is an inherited metabolic disorder caused by a genetic defect in a liver enzyme responsible for detoxifying of ammonia. Individuals with OTC deficiency can develop elevated levels of ammonia in the blood, potentially resulting in severe consequences, including cumulative and irreversible neurological damage, coma, and death. The most severe form presents shortly after birth and occurs more commonly in boys than girls.
This is a Phase 1/2/3, open-label, multicenter study evaluating the safety, efficacy, and dose of ECUR-506 in male babies with neonatal-onset OTC deficiency. The primary objective is to evaluate the safety, tolerability, and efficacy of up to three dose levels of ECUR-506 following intravenous (IV) administration of a single dose.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Interventio / Hoito
Yksityiskohtainen kuvaus
The study drug, ECUR-506, is an investigational gene editing therapy. Gene editing is an approach used to repair, replace, or introduce functional copies of genes that are not working properly. ECUR-506 contains a functional copy of the OTC gene, along with a gene to encode an editing enzyme that enables insertion of the OTC gene into the genome. The study drug is administered as a single IV infusion. Because genes cannot enter cells on their own, ECUR-506 uses a delivery system based on adeno-associated virus (AAV), a commonly used viral vector, to transport the genetic material into cells.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 3
Yhteystiedot ja paikat
Opiskelupaikat
-
-
New South Wales
-
Sydney, New South Wales, Australia
- The Children's Hospital at Westmead
-
-
Victoria
-
Melbourne, Victoria, Australia, 3052
- The Royal Children's Hospital
-
-
-
-
-
Barcelona, Espanja, 08950
- Hopsital Sant Joan de Deu
-
Madrid, Espanja, 28041
- Hospital Universitario 12 de Octubre
-
-
-
-
-
London, Yhdistynyt kuningaskunta
- Great Ormond Street Hospital
-
Newcastle upon Tyne, Yhdistynyt kuningaskunta
- The Newcastle upon Tyne Hospitals NHS Foundation Trust- Great North Children's Hospital
-
-
-
-
California
-
Los Angeles, California, Yhdysvallat, 90095
- UCLA Mattel Children's Hospital
-
-
Colorado
-
Aurora, Colorado, Yhdysvallat, 80045
- Children's Hospital of Colorado, Anshutz Medical Campus
-
-
Georgia
-
Atlanta, Georgia, Yhdysvallat, 30322
- Emory University School of Medicine
-
-
Illinois
-
Chicago, Illinois, Yhdysvallat, 60611
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
New York
-
New York, New York, Yhdysvallat, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Oregon
-
Portland, Oregon, Yhdysvallat, 97239
- Oregon Health and Science University
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Key Inclusion Criteria:
- Male sex
- Gestational or adjusted (corrected) gestational age ≥ 37 weeks
- Age at screening is 24 hours to 7 months
- Weight ≥ 3.5 kg and ≤ 13.5 kg at screening
- Has received age-appropriate vaccinations
- Genetically confirmed OTCD defined by genetic confirmation of an OTC variant (pathogenic or likely pathogenic) associated with severe neonatal OTCD defined below in Inclusion Criteria #7 or has the same OTC variant as a family member who had severe neonatal OTCD within first week of life.
- Severe neonatal OTCD defined by hyperammonemic crisis with elevated ammonia level of >560 μmol/L and clinical symptoms within first week of life, and currently receiving treatment with both dietary protein restriction and nitrogen scavenger therapy.
- Current or historical biochemical profile consistent with OTCD
- Participant's parent(s)/LAR must be able to comprehend and be willing to provide a signed IRB/IEC-approved ICF.
Key Exclusion Criteria:
- Neonatal diagnosis of severe to profound Hypoxic Ischemic Encephalopathy due to birth injury
- Requiring urgent liver transplant due to liver failure as assessed by the PI.
- Contiguous gene deletion involving the OTC gene and including at least the CYBB gene on the telomeric side or the TSPAN7 gene on the centromeric side.
- Known or suspected major organ injury/dysfunction/anomalies.
- Vital sign and laboratory abnormalities outside of reference ranges.
- Treatment with any other gene therapy or gene editing therapy
- Co-enrollment in any other study unless approved by the sponsor.
- Any condition, that in the opinion of the Investigator, would compromise the safety of the participant or study data
- Documented vertical transmission of HepA/HepB/HepC
- Documented in-utero teratogen, substance, and/or alcohol exposure, which in the opinion of the Investigator may increase the participant's risk of developmental delays, congenital anomalies, and/or significant medical complications
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei satunnaistettu
- Inventiomalli: Peräkkäinen tehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Low Dose Level
Participants will receive the Low Dose of ECUR-506 delivered one time via IV Infusion. |
ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene. |
|
Kokeellinen: Intermediate Dose Level
Participants will receive an intermediate dose of ECUR-506 delivered on time via IV infusion |
ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene. |
|
Kokeellinen: High Dose Level
Participants will receive a higher dose of ECUR-506 delivered one time via IV infusion. |
ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Treatment-emergent adverse events (incidence, severity, seriousness, and relatedness)
Aikaikkuna: Over 24 weeks post infusion
|
Toxicity is graded in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Adverse events (AEs) are reported based on clinical laboratory tests, vital signs, physical examinations, Pediatric Neurologist exam parameters, electrocardiograms, and any other medically indicated assessments from the time informed consent is signed through the end of the safety follow-up period. AEs are considered to be treatment emergent (TEAE) if they occur or worsen in severity following the administration of the study treatment. TEAEs are considered treatment-related if relationship to study drug is possibly related, probably related, or definitely related. |
Over 24 weeks post infusion
|
|
Physical exam parameters
Aikaikkuna: Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
Safety- (Includes PI assessment of General Appearance, Dermatological, HEENT, Lymphatic, Respiratory, Cardiovascular, Gastrointestinal, Musculoskeletal, Neurological (Cranial Nerve Function, Motor System Function, Sensory System Function, Primitive Reflexes)) |
Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
|
Vital sign parameters
Aikaikkuna: Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
Safety- (Includes PI assessment of Systolic Blood Pressure, Diastolic Blood Pressure, Pulse Rate, Respiratory Rate, Temperature) |
Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
|
Pediatric neurologist exam parameters
Aikaikkuna: Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
Safety- (Includes Pediatric Neurologist assessment of Neurological status by review of Cranial Nerve Function, Motor System Function, Sensory System Function, Primitive Reflexes.) |
Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
|
Blood safety tests including hematology, serum chemistry, liver function tests, coagulation tests
Aikaikkuna: as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
Safety- (Blood Safety tests to be reviewed in relation to established normal ranges for each assessment for the applicable age group) |
as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
|
Urinalysis evaluations
Aikaikkuna: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Toxicity is graded in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Adverse events (AEs) are reported based on clinical laboratory tests, vital signs, physical examinations, electrocardiograms, and any other medically indicated assessments from the time informed consent is signed through the end of the safety follow-up period. AEs are considered to be treatment emergent (TEAE) if they occur or worsen in severity following the administration of the study treatment. TEAEs are considered treatment-related if relationship to study drug is possibly related, probably related, or definitely related. |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
12 lead ECG parameters
Aikaikkuna: as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
Safety- (Includes PI review of Heart Rate, PR Interval, RR Interval, QRS Duration, QT Interval, QTcF Interval, Overall Interpretation) |
as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
|
Complete clinical response
Aikaikkuna: Over 24 weeks post infusion
|
Discontinuation of scavenger medication for a minimum duration of 28 days without reductions in prescribed daily protein intake during this time period by end of study. |
Over 24 weeks post infusion
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Number of HAEs/person-year
Aikaikkuna: Day 1 post dose through Week 24
|
Key Secondary Endpoint: Pharmacodynamics and Efficacy |
Day 1 post dose through Week 24
|
|
qPCR measurement to evaluate the clearance of both vectors in body fluids over time
Aikaikkuna: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Pharmacokinetics |
Over 24 weeks post infusion
|
|
Incidence of hyperammonemic episode (HAE)
Aikaikkuna: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Pharmacodynamics and Efficacy |
Over 24 weeks post infusion
|
|
Incidence and number of hyperammonemic episodes (HAE/HAC) resulting in hospitalization
Aikaikkuna: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Pharmacodynamics and Efficacy |
Over 24 weeks post infusion
|
|
Overall and by hospitalization severity (Mild: adjustment of dietary protein intake and oral scavenger medication / Moderate: cessation of dietary protein intake and initiation of IV scavenger therapy / Severe: requirement for hemodialysis)
Aikaikkuna: Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants
|
Supportive Secondary Endpoint: Pharmacodynamics and Efficacy. |
Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants
|
|
Duration of hospitalization for each HAE/HAC
Aikaikkuna: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Pharmacodynamics and Efficacy |
Over 24 weeks post infusion
|
|
Requirement for Intensive Care Unit (ICU) care during hospitalization for each HAE/HAC
Aikaikkuna: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Pharmacodynamics and Efficacy |
Over 24 weeks post infusion
|
|
Time to liver transplant from dosing to end of study (EOS)
Aikaikkuna: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Supportive Secondary Endpoint: Efficacy |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Transplant free survival
Aikaikkuna: Time to lever transplant or any-cause death from dosing to EOS
|
Supportive Secondary Endpoint: Efficacy |
Time to lever transplant or any-cause death from dosing to EOS
|
|
Overall survival
Aikaikkuna: Time to any-cause death from dosing to EOS
|
Supportive Secondary Endpoint: Efficacy |
Time to any-cause death from dosing to EOS
|
|
Achieving and maintaining complete clinical response through end of study
Aikaikkuna: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Efficacy |
Over 24 weeks post infusion
|
|
Scavenger drug dose
Aikaikkuna: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Efficacy |
Over 24 weeks post infusion
|
|
Dietary protein intake g/kg/day
Aikaikkuna: Supportive Secondary: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Efficacy |
Supportive Secondary: Over 24 weeks post infusion
|
|
Blood urea nitrogen measurements
Aikaikkuna: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Pharmacodynamics |
Over 24 weeks post infusion
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Clinical Response (CR) defined as reduction in baseline standard of care therapy
Aikaikkuna: Assessed at Week 24
|
Efficacy |
Assessed at Week 24
|
|
Serum Neurofilament Light Chain
Aikaikkuna: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Safety |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Number of participants with antibodies to AAVrh79 capsid in blood
Aikaikkuna: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Pharmacodynamics |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Number of participants with antibodies to hOTC transgene in blood
Aikaikkuna: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Pharmacodynamics |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Number of participants with antibodies to M2PCSK9 transgene in blood
Aikaikkuna: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Pharmacodynamics |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Incidence and time to medical management adjustments based on iECURE guidance (protein diet or scavenger medication)
Aikaikkuna: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Efficacy |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Fasting plasma ammonia
Aikaikkuna: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Pharmacodynamics |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Fasting plasma citrulline and fasting plasma glutamine levels
Aikaikkuna: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Pharmacodynamics |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Serum PCSK9
Aikaikkuna: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Pharmacodynamics |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Urinary excretion of phenylacetate metabolites
Aikaikkuna: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Urinary phenylacetate (mcg/mL), urinary phenylacetylglutamine (mcg/mL), urinary phenylacetate/ phenylglutamine ratio. |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Urinary excretion of orotic acid metabolites.
Aikaikkuna: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Urinary orotic acid (mmol/ mol creatinine), urinary uracil (mmol/mol creatinine). |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Urinary nitrogen to urinary creatinine ratio.
Aikaikkuna: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Urinary nitrogen to urinary creatinine ratio (mg/dL) |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Change from baseline at Week 24 post infusion in length.
Aikaikkuna: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Length measured in centimeters. |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Change from baseline at Week 24 post infusion in weight.
Aikaikkuna: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Weight measured in kilograms. |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Percent liver transduction via ISH/IF (in-situ hybridization / Immunofluorescence)"at Wk 24 collected by liver biopsy.
Aikaikkuna: The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
|
Pharmacodynamics |
The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
|
|
Assess the potential on and "off" target editing by amplicon-seq in liver tissue samples of participants who received ECUR-506.
Aikaikkuna: The following will be assessed at week 24 if liver biopsy tissue sample is sufficient.
|
Pharmacodynamics |
The following will be assessed at week 24 if liver biopsy tissue sample is sufficient.
|
|
Assess potential off-target editing with AAV vector ITR insertion by ITR-seq in liver tissue samples of participants who received ECUR-506
Aikaikkuna: The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
|
Pharmacodynamics |
The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
|
|
Assess for potential genetic changes in the liver tissue, collected by liver biopsy, through long read sequencing, in participants who have received ECUR-506
Aikaikkuna: The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
|
Pharmacodynamics |
The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
|
|
With an observed genetic safety signal, genetic analysis of Whole Blood DNA may be performed on samples collected and stored at screening and week 24, in the event of an observed genomic safety signal.
Aikaikkuna: Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants.
|
Safety |
Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants.
|
|
Change from baseline at Week 24 post infusion in Bayley Scales of Infant and Toddler Development 4th Ed (BSID-4) for the Cognitive, Language, and Motor scales
Aikaikkuna: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Total Raw Scores, Growth Score Values (GSVs), and Age Equivalent Scores will be analyzed; Raw Scores range 0-162; GSVs range 428-599; Age Equivalent Scores range 1-42 months; a higher score reflects a higher level of skill. |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Quality of Life, as measured by the Pediatric QOL inventory Infant Scale (PedsQL-IS)
Aikaikkuna: Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants.
|
Quality of Life |
Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants.
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojohtaja: George Diaz, M.D., Ph.D, iECURE, Inc.
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
- Hermoston sairaudet
- UCD
- Keskushermoston sairaudet
- Maksasairaus
- Geneettiset sairaudet, synnynnäiset
- X-linkitetty
- Ammoniakki
- Vastasyntynyt
- Aivojen sairaudet
- Metaboliset sairaudet
- Aineenvaihdunta
- Aineenvaihdunta, synnynnäiset virheet
- Ureasyklin häiriöt
- Maksansiirto
- Perinnölliset aineenvaihduntahäiriöt
- Aivosairaudet, Metaboliset, Synnynnäiset
- Geneettiset sairaudet, X-Linked
- Synnynnäinen
- Synnynnäiset virheet
- OTC
- Aivosairaudet, Metaboliset
- OTC-puute
- OTCD
- Ornitiini
- Transkarbamylaasi
- Ornitiinin transkarbamylaasin puutos
- Hyperammonemia
- Aminohappoaineenvaihdunta, synnynnäiset virheet
- Korkea ammoniakki
- NH4
- Neurometaboliset häiriöt
Muita asiaankuuluvia MeSH-ehtoja
- Patologiset prosessit
- Ruoansulatuskanavan sairaudet
- Synnynnäiset, perinnölliset ja vastasyntyneiden sairaudet ja poikkeavuudet
- Patologiset tilat, merkit ja oireet
- Ravitsemukselliset ja aineenvaihduntataudit
- Geneettiset sairaudet, synnynnäiset
- Maksasairaudet
- Aivojen sairaudet
- Hermoston sairaudet
- Keskushermoston sairaudet
- Metaboliset sairaudet
- Aineenvaihdunta, synnynnäiset virheet
- Aivosairaudet, aineenvaihdunta
- Geneettiset sairaudet, X-Linked
- Ornitiinikarbamoyylitransferaasin puutossairaus
- Ureasyklin häiriöt, synnynnäiset
- Aminohappoaineenvaihdunta, synnynnäiset virheet
- Hyperammonemia
- Aivosairaudet, Metaboliset, Synnynnäiset
Muut tutkimustunnusnumerot
- ECUR-506-OTC-101
- OTC-HOPE (Muu tunniste: iECURE, Inc.)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .